Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 14, Issue 9, Pages 1134-1163Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0122
Keywords
-
Categories
Funding
- Astellas LLC
- AstraZeneca Pharmaceuticals LP
- Clovis Oncology
- GOG Foundation
- NRG Oncology
- TESARO, Inc.
- Janssen Pharmaceutica Products, LP
- NCI
- Novartis Pharmaceuticals Corporation
- Synta Pharmaceuticals Corp.
- Amgen Inc.
- Endocyte, Inc.
- Genentech, Inc.
- Vascular Biogenics Ltd
- Azaya Therapeutics, Inc.
- BIND Therapeutics, Inc.
- Millennium Pharmaceuticals, Inc.
- Navidea Biopharmaceuticals
- Pfizer Inc.
- PharmaMar
- Bristol-Myers Squibb Company
- Eisai Inc.
Ask authors/readers for more resources
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for the 2016 update. The new LCOHs algorithms include clear cell carcinomas, mucinous carcinomas, and grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. The LCOHs also include carcinosarcomas (malignant mixed Mullerian tumors of the ovary), borderline epithelial tumors (also known as low malignant potential tumors), malignant sex cord-stromal tumors, and malignant germ cell tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
